SEI Investments
RLMD icon

SEI Investments’s Relmada Therapeutics RLMD Stock Holding History

SEI Investments’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Buy
166,614
+67,649
+68% +$320K ﹤0.01% 2287
2025
Q4 		$478K Buy
+98,965
New +$332K ﹤0.01% 2522
2025
Q2 		– Sell
-36,230
Closed -$9.78K – 2896
2025
Q1 		$9.78K Hold
36,230
– – ﹤0.01% 2750
2024
Q4 		$18.8K Sell
36,230
-90
-0.2% -$220 ﹤0.01% 2714
2024
Q3 		$118K Hold
36,320
– – ﹤0.01% 2540
2024
Q2 		$109K Hold
36,320
– – ﹤0.01% 2521
2024
Q1 		$169K Hold
36,320
– – ﹤0.01% 2452
2023
Q4 		$150K Buy
36,320
+90
+0.2% +$266 ﹤0.01% 2477
2023
Q3 		$109K Hold
36,230
– – ﹤0.01% 2506
2023
Q2 		$89.1K Sell
36,230
-739
-2% -$2.04K ﹤0.01% 2582
2023
Q1 		$83.5K Sell
36,969
-64,376
-64% -$222K ﹤0.01% 2595
2022
Q4 		$354K Buy
+101,345
New +$890K ﹤0.01% 2145

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SEI Investments's RLMD Position: Q1 2026 in Review

SEI Investments increased its Relmada Therapeutics (RLMD) stake by 68% in Q1 2026, buying an estimated $320K and bringing the position to 166,614 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2287.

SEI Investments first reported a position in RLMD in Q4 2022 and has held it in 12 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • SEI Investments held 166,614 shares of Relmada Therapeutics worth $1.16M as of Q1 2026.
  • SEI Investments bought 67,649 Relmada Therapeutics shares in Q1 2026, an estimated $320K.
  • Relmada Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #2287 holding.
  • SEI Investments first reported a position in Relmada Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.